Delft/Utrecht, May 2026 – Free Bee International and Lyla are proud to announce that Lyla has licensed Free Bee’s newly patented radiation detection technology. This innovation is specifically designed to enhance the quality control (QC) of radioisotopes used in advanced cancer therapies.
The technology was developed by Prof. em. Frederik J. Beekman, CEO and founder of Free Bee International. It addresses critical challenges in ensuring the purity and reliability of radiopharmaceuticals, directly contributing to safer and more effective oncological treatments.
Strategic Partnership
The patent, owned by Free Bee International, has been licensed to Lyla, who will spearhead further development and global commercialization. To ensure a seamless transition and continued innovation, Prof. Beekman will join Lyla as a Senior Advisor. “This collaboration exemplifies the translation of academic innovation into clinical practice,” said Prof. Beekman. “Our goal is to set new quality control standards in radiopharmaceutical applications and accelerate the advancement of targeted radionuclide therapies.”
This collaboration exemplifies the translation of academic innovation into clinical practice.” –
Prof. Beekman.
Removing QC Bottlenecks
Lyla will integrate this technology to advance its mission of enabling the clinical adoption of these therapies by removing critical QC bottlenecks.
“As targeted radionuclide therapies gain momentum globally, this technology is a vital piece of the puzzle,” said Ernst van der Wal, Cofounder of Lyla. “It enables us to develop products that guarantee safe, high-quality applications for patients who need them most.”
About Free Bee International
Founded in 2023 by Prof. Frederik J. Beekman, Free Bee International develops advanced imaging and quality control methods to improve patient care. The company focuses on bridging the gap between scientific innovation and real-world medical instrumentation, reconstruction, and processing technologies.
About Lyla
Lyla specializes in quality control technologies for radiopharmaceutical applications, combining expertise in physics, software, and hardware. Rooted in academic excellence, Lyla translates complex science into practical tools that support safer and more effective targeted radionuclide therapies.
